Company Filing History:
Years Active: 2008
Title: Innovations in Antituberculosis Compounds by Nigel Leslie Hywel-Jones
Introduction
Nigel Leslie Hywel-Jones is an accomplished inventor based in Bangkok, Thailand. He has made significant contributions to the field of biotechnology, particularly in the development of antituberculosis compounds. His work focuses on the isolation and application of novel alkaloids that show promise in treating tuberculosis.
Latest Patents
Hywel-Jones holds a patent for antituberculosis compounds, specifically Hirsutellones A, B, and C. These three new alkaloids are produced in cultures of specific fungus strains, such as strain BCC 2594 and strain BCC 7579. The Hirsutellones have demonstrated potent growth inhibitory activity against the H37Ra strain of tuberculosis, with a minimum inhibitory concentration (MIC) value of 0.78 µg/ml. Importantly, these compounds exhibit weak or no cytotoxicity to mammalian cells, indicating their potential as safe therapeutic agents. The patent also describes methods for isolating the Hirsutellones, which could facilitate further research and development.
Career Highlights
Hywel-Jones is affiliated with the National Center for Genetic Engineering & Biotechnology, which is part of the National Science & Technology Development Agency. His role at this institution allows him to engage in cutting-edge research and contribute to advancements in genetic engineering and biotechnology.
Collaborations
Some of his notable coworkers include Masahiko Isaka and Sayanh Somrithipol. Their collaborative efforts in research have likely enhanced the development and application of the Hirsutellones.
Conclusion
Nigel Leslie Hywel-Jones is a key figure in the fight against tuberculosis through his innovative work on Hirsutellones A, B, and C. His contributions to biotechnology and his patent for these compounds highlight the importance of research in developing effective treatments for infectious diseases.